HomeComparePRLX vs MRK

PRLX vs MRK: Dividend Comparison 2026

PRLX yields 2000000.00% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PRLX wins by $4.879226400974806e+39M in total portfolio value
10 years
PRLX
PRLX
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full PRLX calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — PRLX vs MRK

📍 PRLX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPRLXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PRLX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PRLX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PRLX
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, PRLX beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PRLX + MRK for your $10,000?

PRLX: 50%MRK: 50%
100% MRK50/50100% PRLX
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

PRLX
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PRLX buys
0
MRK buys
0
No recent congressional trades found for PRLX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPRLXMRK
Forward yield2000000.00%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$4.879226400974806e+39M$56.8K
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$9,798.13
Total dividends collected$4.879195005460081e+39M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PRLX vs MRK ($10,000, DRIP)

YearPRLX PortfolioPRLX Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,206$366.19+$200.00MPRLX
2$3,738,731,768,458$3,738,517,757,009.35$12,650$502.35+$3738731.76MPRLX
3$65,315,062,866,930,490$65,311,062,423,938,240.00$14,407$694.19+$65315062866.92MPRLX
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$16,585$967.82+$1066400830062625.00MPRLX
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$19,342$1,363.89+$16272182796453826560.00MPRLX
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$22,913$1,947.19+$2.3205424011366188e+23MPRLX
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$27,662$2,823.89+$3.0927990661046884e+27MPRLX
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$34,159$4,173.35+$3.8524105697352695e+31MPRLX
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$43,337$6,308.80+$4.484688260147987e+35MPRLX
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$56,776$9,798.13+$4.879226400974806e+39MPRLX

PRLX vs MRK: Complete Analysis 2026

PRLXStock

Parallax Health Sciences, Inc. builds and expands an integrated digital healthcare network with products and services that provide remote communication, diagnosis, treatment, and monitoring of patients. The company offers remote healthcare products, including patent pending software and mobile apps, and other services, as well as electronic kits and devices from third-party licensed platforms that are designated towards a patient's primary health concern, such as diabetes, blood pressure, cardiovascular, general monitoring, etc.; and audio and video options that interface with the patient's healthcare providers. It also provides prescription medication dosage monitoring services; and behavioral health products comprising REBOOT, a proprietary behavioral health technology for an individual or an organization to transform the cost of treating and managing chronic illnesses that include pulmonary-COPD-asthma, diabetes, and cardiovascular diseases by effecting the modification of behavior in patients being treated for these chronic diseases. In addition, the company offers diagnostics products, which comprise Target System, a proprietary POC diagnostic immunoassay testing platform; and test cartridges for the areas of infectious diseases, cardiac markers, drugs of abuse, and various other medical conditions, as well as VT-1000 desktop analyzers, target antigen detection systems, and other products. Further, it provides SPARKS Mobile, a target system hand-held analyzer; COMPASS for behavioral modification; Fotodigm platform for remote patient monitoring, telehealth, and POC diagnostic testing services; and Intrinsic Code technology for actionable insights to behavior modification. The company was formerly known as Endeavor Power Corporation and changed its name to Parallax Health Sciences, Inc. in January 2014. Parallax Health Sciences, Inc. was founded in 2005 and is headquartered in Santa Monica, California.

Full PRLX Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this PRLX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PRLX vs SCHDPRLX vs JEPIPRLX vs OPRLX vs KOPRLX vs MAINPRLX vs JNJPRLX vs ABBVPRLX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.